PAVmed Inc
NASDAQ:PAVM
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    1.5700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.5200/ 20
  • Ask / Lots
    2.0800/ 1
  • Open / Previous Close
    0.0000 / 1.5700
  • Day Range
    ---
  • 52 Week Range
    1.5700
    ---
    9.0000
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 13, 2024

      Show headlines and story abstract

    • 8:43PM ET on Monday May 13, 2024 by PR Newswire
      Companies Mentioned: PAVM, LUCD

      Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date

      Veris Health completes MOU with The Ohio State's James Cancer Hospital

      Conference call and webcast to be held tomorrow, May 14th at 8:30 AM EDT

    • 8:43PM ET on Monday May 13, 2024 by Dow Jones
      Companies Mentioned: PAVM, LUCD
      =================== =================== Basic and Diluted shares outstanding 8,695 6,473 Non-GAAP adjusted (loss) income per share $(0.99) $(1.73) (1) Included in general and administrative expenses in the financial statements. (2) Included in other income and expenses. (3) Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses: Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses (in thousands except per-share For the three months ended amounts) March 31, 2024 2023 ------------------ ------------------ Cost of revenue $ 1,744 $ 1,346 Stock-based compensation expense(3) (36) (23) ------------------ ------------------ Net cost of revenue 1,708 1,323 ================== ================== Amortization of acquired intangible assets 372 505 Sales and marketing 4,311 4,539 Stock-based compensation expense(3) (403) (444) ------------------ ------------------ Net sales and marketing 3,908 4,095 ================== ================== General and administrative 6,678 10,407 Depreciation expense (214) (222) ResearchDx acquisition/settlement paid in stock -- (713) Stock-based compensation expense(3) (1,078) (3,588) ------------------ ------------------ Net general and administrative 5,386 5,884 ================== ================== Research and development 1,941 4,050 Stock-based compensation expense(3) (365) (364) ------------------ ------------------ Net research and development 1,576 3,686 ================== ================== Total operating expenses 15,046 20,847 Depreciation and amortization expense (586) (727) ResearchDx acquisition/settlement paid in stock -- (713) Stock-based compensation expense(3) (1,882) (4,419) ------------------ ------------------ Net operating expenses $ 12,578 $ 14,988 ================== ==================

    • 8:43PM ET on Monday May 13, 2024 by Dow Jones
      Companies Mentioned: PAVM, LUCD
      =================== =================== Basic and Diluted shares outstanding 8,695 6,473 Non-GAAP adjusted (loss) income per share $(0.99) $(1.73) (1) Included in general and administrative expenses in the financial statements. (2) Included in other income and expenses. (3) Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses: Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses (in thousands except per-share For the three months ended amounts) March 31, 2024 2023 ------------------ ------------------ Cost of revenue $ 1,744 $ 1,346 Stock-based compensation expense(3) (36) (23) ------------------ ------------------ Net cost of revenue 1,708 1,323 ================== ================== Amortization of acquired intangible assets 372 505 Sales and marketing 4,311 4,539 Stock-based compensation expense(3) (403) (444) ------------------ ------------------ Net sales and marketing 3,908 4,095 ================== ================== General and administrative 6,678 10,407 Depreciation expense (214) (222) ResearchDx acquisition/settlement paid in stock -- (713) Stock-based compensation expense(3) (1,078) (3,588) ------------------ ------------------ Net general and administrative 5,386 5,884 ================== ================== Research and development 1,941 4,050 Stock-based compensation expense(3) (365) (364) ------------------ ------------------ Net research and development 1,576 3,686 ================== ================== Total operating expenses 15,046 20,847 Depreciation and amortization expense (586) (727) ResearchDx acquisition/settlement paid in stock -- (713) Stock-based compensation expense(3) (1,882) (4,419) ------------------ ------------------ Net operating expenses $ 12,578 $ 14,988 ================== ==================

    • 8:01AM ET on Monday May 13, 2024 by PR Newswire
      Companies Mentioned: PAVM, LUCD

      Quarterly EsoGuard(R) test volume increased 10 percent

      Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering

      MolDX pre-submission meeting scheduled for July 17, 2024

    • 8:01AM ET on Monday May 13, 2024 by Dow Jones
      Companies Mentioned: PAVM, LUCD

Peers Headlines